Page last updated: 2024-10-18

dihydroxyphenylalanine and Acquired Immunodeficiency Syndrome

dihydroxyphenylalanine has been researched along with Acquired Immunodeficiency Syndrome in 1 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Montefiori, DC1
Zhou, JY1

Other Studies

1 other study available for dihydroxyphenylalanine and Acquired Immunodeficiency Syndrome

ArticleYear
Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus in vitro.
    Antiviral research, 1991, Volume: 15, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; CD2 A

1991